252 related articles for article (PubMed ID: 32673292)
21. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
22. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors.
Le Maux Chansac B; Moretta A; Vergnon I; Opolon P; Lécluse Y; Grunenwald D; Kubin M; Soria JC; Chouaib S; Mami-Chouaib F
J Immunol; 2005 Nov; 175(9):5790-8. PubMed ID: 16237071
[TBL] [Abstract][Full Text] [Related]
23. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-33, a Potential Cytokine Expressed in Tumor Microenvironment Involves in Antitumor Immunotherapy Through Facilitates CD8
Li X; Lv Q; Feng Y; Gu Y; Xia R; Ma J; He H; Zhu Y
J Interferon Cytokine Res; 2018 Nov; 38(11):491-499. PubMed ID: 30452317
[TBL] [Abstract][Full Text] [Related]
25. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
Jiang W; Zhang C; Tian Z; Zhang J
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
[TBL] [Abstract][Full Text] [Related]
26. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
27. Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.
O'Brien SM; Klampatsa A; Thompson JC; Martinez MC; Hwang WT; Rao AS; Standalick JE; Kim S; Cantu E; Litzky LA; Singhal S; Eruslanov EB; Moon EK; Albelda SM
Cancer Immunol Res; 2019 Jun; 7(6):896-909. PubMed ID: 31053597
[TBL] [Abstract][Full Text] [Related]
28. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer.
Bruno A; Focaccetti C; Pagani A; Imperatori AS; Spagnoletti M; Rotolo N; Cantelmo AR; Franzi F; Capella C; Ferlazzo G; Mortara L; Albini A; Noonan DM
Neoplasia; 2013 Feb; 15(2):133-42. PubMed ID: 23441128
[TBL] [Abstract][Full Text] [Related]
29. Accumulation of Tumor-Infiltrating CD49a
Sun H; Liu L; Huang Q; Liu H; Huang M; Wang J; Wen H; Lin R; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
Cancer Immunol Res; 2019 Sep; 7(9):1535-1546. PubMed ID: 31311791
[TBL] [Abstract][Full Text] [Related]
30. NK cell phenotypic modulation in lung cancer environment.
Jin S; Deng Y; Hao JW; Li Y; Liu B; Yu Y; Shi FD; Zhou QH
PLoS One; 2014; 9(10):e109976. PubMed ID: 25299645
[TBL] [Abstract][Full Text] [Related]
31. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients.
Lim SA; Kim J; Jeon S; Shin MH; Kwon J; Kim TJ; Im K; Han Y; Kwon W; Kim SW; Yee C; Kim SJ; Jang JY; Lee KM
Front Immunol; 2019; 10():496. PubMed ID: 31024520
[TBL] [Abstract][Full Text] [Related]
32. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
33. Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.
Goding SR; Yu S; Bailey LM; Lotze MT; Basse PH
Clin Immunol; 2017 Apr; 177():76-86. PubMed ID: 27377534
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer.
Lin M; Liang SZ; Shi J; Niu LZ; Chen JB; Zhang MJ; Xu KC
Immunol Lett; 2017 Nov; 191():10-15. PubMed ID: 28916277
[TBL] [Abstract][Full Text] [Related]
35. IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma.
Zheng Y; Li Y; Tang B; Zhao Q; Wang D; Liu Y; Guo M; Zhao S; Qi Y; Zhang Y; Huang L
Cancer Immunol Immunother; 2020 Nov; 69(11):2371-2380. PubMed ID: 32524362
[TBL] [Abstract][Full Text] [Related]
36. PD-1
Trefny MP; Kaiser M; Stanczak MA; Herzig P; Savic S; Wiese M; Lardinois D; Läubli H; Uhlenbrock F; Zippelius A
Cancer Immunol Immunother; 2020 Aug; 69(8):1505-1517. PubMed ID: 32296919
[TBL] [Abstract][Full Text] [Related]
37. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
38. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
39. Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance.
Zheng X; Qian Y; Fu B; Jiao D; Jiang Y; Chen P; Shen Y; Zhang H; Sun R; Tian Z; Wei H
Nat Immunol; 2019 Dec; 20(12):1656-1667. PubMed ID: 31636463
[TBL] [Abstract][Full Text] [Related]
40. Antigen-Presenting Intratumoral B Cells Affect CD4
Bruno TC; Ebner PJ; Moore BL; Squalls OG; Waugh KA; Eruslanov EB; Singhal S; Mitchell JD; Franklin WA; Merrick DT; McCarter MD; Palmer BE; Kern JA; Slansky JE
Cancer Immunol Res; 2017 Oct; 5(10):898-907. PubMed ID: 28848053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
